http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-1173749-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8c646f75c4f7c6349f35c8fe01934921 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 |
| filingDate | 1981-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 1984-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2712fbc3311f345d75951db2e53f13c |
| publicationDate | 1984-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-1173749-A |
| titleOfInvention | Therapeutic method for treatment of juvenile diabetes mellitus and pharmaceutical composition for such a method |
| abstract | "Therapeutic method for the treatment of juvenile diabetes mellitus and pharmaceutical composition for such a method". ABSTRACT OF THE DISCLOSURES The oral or parenteral administration of L-carnitine or certain L-acyl carnitines, typically L-propionyl carnitine, or the pharmacological salts thereof, permits a considerable reduction (from 20 to approx. 50%) of the daily dose of insulin that should be administered to patients affected by juvenile diabetes mellitus to restore normal blood glucose levels. Moreover, L-carnitine and such acyl carnitines actively inhibit ketoacidosis, thus avoiding the risk of ketoacidosic coma in such patients. |
| priorityDate | 1980-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 173.